Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma

British Journal of Dermatology

Volumn 169, Issue 2, 2013, Pages 320-328

  Safaee Ardekani, G ^a   Jafarnejad, S M ^a   Khosravi, S ^a   Martinka, M ^a   Ho, V ^a   Li, G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; AGE; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CORRELATIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENDER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NEVUS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; ULCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEVUS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84881584493     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12351     Document Type: Article

References (35)

1. Diepgen TL, Mahler V,. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61): 1-6.
2. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society, 2011.
3. Inamdar GS, Madhunapantula SV, Robertson GP,. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010; 80: 624-37.
4. Davies H, Bignell GR, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
5. Gorden A, Osman I, Gai W, et al,. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003; 63: 3955-7.
6. Dong J, Phelps RG, Qiao R, et al,. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63: 3883-5.
7. Aguissa-Toure AH, Li G,. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci 2012; 69: 1475-91.
8. Wan PT, Garnett MJ, Roe SM, et al,. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67.
9. Rubinstein JC, Sznol M, Pavlick AC, et al,. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8: 67.
10. Flaherty KT, Puzanov I, Kim KB, et al,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
11. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
12. Sigma-Aldrich. Anti-BRAF (431-445) antibody produced in rabbit. Available at: http://www.sigmaaldrich.com/catalog/product/SIGMA/B1687 (last accessed 13 May 2013).
13. Vultur A, Villanueva J, Herlyn M,. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011; 17: 1658-63.
14. Dhomen N, Marais R,. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009; 23: 529-45.
15. Fecher LA, Cummings SD, Keefe MJ, Alani RM,. Toward a molecular classification of melanoma. J Clin Oncol 2007; 25: 1606-20.
16. Platz A, Egyhazi S, Ringborg U, Hansson J,. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395-405.
17. Thomas NE,. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006; 16: 97-103.
18. Long GV, Menzies AM, Nagrial AM, et al,. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46.
19. Curtin JA, Fridlyand J, Kageshita T, et al,. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
20. Liu W, Kelly JW, Trivett M, et al,. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007; 127: 900-5.
21. Thomas NE, Edmiston SN, Alexander A, et al,. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 991-7.
22. Houben R, Becker JC, Kappel A, et al,. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6.
23. Ugurel S, Thirumaran RK, Bloethner S, et al,. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2007; 2: e236.
24. Kumar R, Angelini S, Snellman E, Hemminki K,. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004; 122: 342-8.
25. Hoeflich KP, Gray DC, Eby MT, et al,. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006; 66: 999-1006.
26. Arozarena I, Sanchez-Laorden B, Packer L, et al,. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2011; 19: 45-57.
27. Omholt K, Platz A, Kanter L, et al,. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9: 6483-8.
28. Dankort D, Curley DP, Cartlidge RA, et al,. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544-52.
29. Shinozaki M, Fujimoto A, Morton DL, Hoon DS,. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10: 1753-7.
30. Edlundh-Rose E, Egyházi S, Omholt K, et al,. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16: 471-8.
31. Safaee AG, Jafarnejad SM, Tan L, et al,. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE 2012; 7: e47054.
32. Goel VK, Ibrahim N, Jiang G, et al,. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009; 28: 2289-98.
33. Uribe P, Andrade L, Gonzalez S,. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 2006; 126: 161-6.
34. Tanami H, Imoto I, Hirasawa A, et al,. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 2004; 23: 8796-804.
35. Kondo T, Nakazawa T, Murata S, et al,. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 2007; 38: 1810-18.